Clinical Efficacy of House Dust Mite-specific Immunotherapy in Asthmatic Children

Tsai, Tzu Chun; Lu, Jen Her; Chen, Shu Jen; Tang, Ren-Bin

doi:10.1016/s1875-9572(10)60004-6

Cited by 27 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All these studies demonstrated that the AIT treated group had a significant decline in the medication score compared with the placebo group (54,55,134,234).…”

Section: Asthma Controlmentioning

confidence: 98%

“…The efficacy of AIT in asthma is measured using symptom scores, medication scores, as well as lung function test (55,134,(233)(234)(235). The symptom and medication scores are frequently used as primary endpoints in AIT trials.…”

Section: Asthma Controlmentioning

confidence: 99%

“…The nocturnal asthma symptoms are scored from 0 to 4 points according to the frequency of nocturnal and early morning awakening by asthma. The total asthma symptom score (TASS) is the sum of daytime and nocturnal asthma symptoms scores, and generally been evaluated monthly in most studies (54,55,134,234,235).…”

Section: Asthma Controlmentioning

confidence: 99%

“…Some studies have evaluated asthma control ("well controlled" or "totally controlled") and asthma symptom score according to GINA guideline as well as the number of emergency room visits or hospitalisation for asthma attack (234,236,237). In one of the studies, a subsequent post hoc analysis by asthma severity revealed significant clinical benefit in the AIT group with moderate, persistent asthma at baseline with 401-800 μg budesonide/day; with greater achievement of well-control asthma and totally controlled asthma (236).…”

Section: Asthma Controlmentioning

confidence: 99%

“…The parameters included FEV 1 % predicted, PEF rate in the morning and night, PEF% predicted value as well as brochoprovocation tests (54,55,(233)(234)(235)237). However, within-group analysis in some studies failed to demonstrate significant differences between AIT and control groups (233,234,236).…”

Section: Asthma Controlmentioning

confidence: 99%

See 4 more Smart Citations

Chinese Guideline on allergen immunotherapy for allergic rhinitis

et al. 2017

View full text Add to dashboard Cite

“…All these studies demonstrated that the AIT treated group had a significant decline in the medication score compared with the placebo group (54,55,134,234).…”

Section: Asthma Controlmentioning

confidence: 98%

Section: Asthma Controlmentioning

confidence: 99%

Section: Asthma Controlmentioning

confidence: 99%

Section: Asthma Controlmentioning

confidence: 99%

Section: Asthma Controlmentioning

confidence: 99%

See 3 more Smart Citations

Chinese Guideline on allergen immunotherapy for allergic rhinitis

et al. 2017

View full text Add to dashboard Cite

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children

Chauhan

Ducharme

2012

Cochrane Database of Systematic Reviews

185

107

View full text Add to dashboard Cite

Background Anti-leukotrienes (5-lipoxygenase inhibitors and leukotriene receptors antagonists) serve as alternative monotherapy to inhaled corticosteroids (ICS) in the management of recurrent and/or chronic asthma in adults and children. Objectives To determine the safety and efficacy of anti-leukotrienes compared to inhaled corticosteroids as monotherapy in adults and children with asthma and to provide better insight into the influence of patient and treatment characteristics on the magnitude of effects. Search methods We searched MEDLINE (1966 to Dec 2010), EMBASE (1980 to Dec 2010), CINAHL (1982 to Dec 2010), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (Dec 2010), abstract books, and reference lists of review articles and trials. We contacted colleagues and the international headquarters of anti-leukotrienes producers. Selection criteria We included randomised trials that compared anti-leukotrienes with inhaled corticosteroids as monotherapy for a minimum period of four weeks in patients with asthma aged two years and older. Data collection and analysis Two review authors independently assessed the methodological quality of trials and extracted data. The primary outcome was the number of patients with at least one exacerbation requiring systemic corticosteroids. Secondary outcomes included patients with at least one exacerbation requiring hospital admission, lung function tests, indices of chronic asthma control, adverse effects, withdrawal rates and biological inflammatory markers. Main results Sixty-five trials met the inclusion criteria for this review. Fifty-six trials (19 paediatric trials) contributed data (representing total of 10,005 adults and 3,333 children); 21 trials were of high methodological quality; 44 were published in full-text. All trials pertained to patients with mild or moderate persistent asthma. Trial durations varied from four to 52 weeks. The median dose of inhaled corticosteroids was quite homogeneous at 200 μg/day of microfine hydrofluoroalkane-propelled beclomethasone or equivalent (HFABDP eq). Patients treated with anti-leukotrienes were more likely to suffer an exacerbation requiring systemic corticosteroids (N = 6077 participants; risk ratio (RR) 1.51, 95% confidence interval (CI) 1.17, 1.96). For every 28 (95% CI 15 to 82) patients treated with anti-leukotrienes instead of inhaled corticosteroids, there was one additional patient with an exacerbation requiring rescue systemic corticosteroids. The magnitude of effect was significantly greater in patients with moderate compared with those with mild airway obstruction (RR 2.03, 95% CI 1.41, 2.91 versus RR 1.25, 95% CI 0.97, 1.61), but was not significantly influenced by age group (children representing 23% of the weight versus adults), anti-leukotriene used, duration of intervention, methodological quality, and funding source. Significant group differences favouring inhaled corticosteroids were noted in most secondary outcomes including patients with at least one e...

show abstract